An Open-Label Long-Term Extension Study of the Safety and Efficacy of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone Deficiency - Versartis Long-Term Extension Study of Somavaratan
Study on Effects of Long-Acting Growth Hormone in Children
Brief description of study.
The purpose of this study is to see how well a longer-acting growth hormone will work in children over a long period of time, and how safe it is.
Detailed description of study
The purpose of this study is to see how well a longer-acting growth hormone will work in children over a long period of time, and how safe it is.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Growth Hormone Deficiency
-
Age: 100 years or below
-
Gender: All
This study investigates the effects of a longer-acting growth hormone in children. The purpose is to understand how well this hormone works over an extended period and assess its safety. Growth hormones are natural substances that help children grow and develop, and this study focuses on a version that lasts longer in the body.
Participants in the study will receive either the investigational growth hormone or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The procedures will include regular monitoring of growth and health indicators to ensure safety and effectiveness.
- Who can participate: Eligibility criteria include children of specific age groups. Additional key factors for participation include health status and previous growth-related treatments.
- Study details: Participants will be given either the investigational growth hormone or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or